Table 5.

Cox proportional hazards model for Grade ≥2 ICANS in lymphoma cohort.

Variable	Univariate analysisa				Multivariate analysis
	HR	Lower 95% CI	Upper 95% CI	P value*	HR	Lower 95% CI	Upper 95% CI	P value*
Age at CAR Tb	1.006	0.988	1.024	0.5
Sex (male)	0.81	0.50	1.31	0.4
CAR T construct (axi-cel)	2.59	1.04	6.44	0.04*	3.15	1.17	8.47	0.02*
ECOG ≥ 1	1.86	1.14	3.04	0.01*	1.45	0.87	2.41	0.2
Lines of therapy prior to CAR Tb	1.035	0.892	1.202	0.6
Bridging therapy prior to CAR T	0.96	0.59	1.57	0.9
Time from diagnosis to CAR T (months)b	0.997	0.991	1.002	0.2
ANCb	1.052	0.987	1.121	0.1
Hemoglobinb	0.781	0.685	0.891	<0.01*	0.897	0.764	1.054	0.2
Plateletsb	1.000	0.997	1.002	0.7
LDHb	1.001	1.001	1.002	<0.01*	1.001	1.000	1.002	0.08
Albuminb	0.388	0.256	0.588	<0.01*	0.673	0.395	1.146	0.1
Prophylactic G-CSFc	1.23	0.71	2.13	0.5	1.04	0.59	1.84	0.9

^*P < 0.05, indicating statistical significance in univariate or multivariate models, is denoted by asterisks.

^aVariables with P < 0.10 in Cox univariate proportional hazards model were included in the multivariate model. The variable of interest, prophylactic G-CSF, was included in the model to study its effect on the development of Grade ≥2 ICANS.

^bContinuous hazard ratio (per unit change in regressor).

^cProphylactic G-CSF refers to exposure to G-CSF prior to CAR T cell infusion.